1. Home
  2. KNSA vs NAVI Comparison

KNSA vs NAVI Comparison

Compare KNSA & NAVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KNSA
  • NAVI
  • Stock Information
  • Founded
  • KNSA 2015
  • NAVI 1973
  • Country
  • KNSA United Kingdom
  • NAVI United States
  • Employees
  • KNSA N/A
  • NAVI N/A
  • Industry
  • KNSA Biotechnology: Pharmaceutical Preparations
  • NAVI Investment Bankers/Brokers/Service
  • Sector
  • KNSA Health Care
  • NAVI Finance
  • Exchange
  • KNSA Nasdaq
  • NAVI Nasdaq
  • Market Cap
  • KNSA 1.6B
  • NAVI N/A
  • IPO Year
  • KNSA 2018
  • NAVI N/A
  • Fundamental
  • Price
  • KNSA $21.77
  • NAVI $12.62
  • Analyst Decision
  • KNSA Strong Buy
  • NAVI Hold
  • Analyst Count
  • KNSA 6
  • NAVI 7
  • Target Price
  • KNSA $37.17
  • NAVI $13.79
  • AVG Volume (30 Days)
  • KNSA 572.9K
  • NAVI 751.7K
  • Earning Date
  • KNSA 04-22-2025
  • NAVI 04-23-2025
  • Dividend Yield
  • KNSA N/A
  • NAVI 5.07%
  • EPS Growth
  • KNSA N/A
  • NAVI N/A
  • EPS
  • KNSA N/A
  • NAVI 1.18
  • Revenue
  • KNSA $423,239,000.00
  • NAVI $848,000,000.00
  • Revenue This Year
  • KNSA $37.21
  • NAVI N/A
  • Revenue Next Year
  • KNSA $1.38
  • NAVI $0.88
  • P/E Ratio
  • KNSA N/A
  • NAVI $10.69
  • Revenue Growth
  • KNSA 56.60
  • NAVI N/A
  • 52 Week Low
  • KNSA $16.56
  • NAVI $12.36
  • 52 Week High
  • KNSA $28.15
  • NAVI $17.56
  • Technical
  • Relative Strength Index (RSI)
  • KNSA 47.67
  • NAVI 34.97
  • Support Level
  • KNSA $22.62
  • NAVI $13.23
  • Resistance Level
  • KNSA $23.42
  • NAVI $13.41
  • Average True Range (ATR)
  • KNSA 0.70
  • NAVI 0.36
  • MACD
  • KNSA -0.18
  • NAVI -0.07
  • Stochastic Oscillator
  • KNSA 3.05
  • NAVI 18.57

About KNSA Kiniksa Pharmaceuticals Ltd.

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Share on Social Networks: